NVCR earnings: next report 2026-10-29, real EPS beat/miss history, analyst consensus Buy, P/E -10.18. Updated 2026-07-23.
Novocure (NVCR) Research Hub
Novocure (NVCR) trades on NASDAQ, CH in the Healthcare (Medical - Devices) sector. As of 2026-09-11, shares last closed at 15.51 USD (-0.77%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -10.18, market cap 1.77B. This hub links to the full technical, earnings and options research available for NVCR.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Devices) |
|---|---|
| Exchange | NASDAQ, CH |
| Last close | 15.51 USD (-0.77%) |
| 52-week range | 13.51 USD – 21.45 USD |
| Trend regime | Range |
| 14-day RSI | 44.3 (Bearish) |
| Trailing P/E | -10.18 |
| Market cap | 1.77B |
| Dividend yield | 0.00% |
| Next earnings | 2026-10-29 |
Available research for NVCR
Covered Call on NVCR: how it works, illustrative setup around the real 15.51 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on NVCR: how it works, illustrative setup around the real 15.51 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on NVCR: how it works, illustrative setup around the real 15.51 USD price, max profit/loss, breakeven and when to use it. Educational.
NVCR technical analysis: range, last 15.51 USD, RSI 44.3, 52w range 13.51 USD–21.45 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is NVCR in?
Novocure (NVCR) is classified under Healthcare (Medical - Devices), listed on NASDAQ, CH.
Is NVCR in an uptrend or downtrend?
As of 2026-09-11, NVCR is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is NVCR's trailing P/E ratio?
NVCR's trailing P/E is -10.18, with a market cap of 1.77B. See the earnings research page for full valuation detail.
When does NVCR next report earnings?
NVCR is next scheduled to report earnings on 2026-10-29, with a consensus EPS estimate of -0.28 USD.